Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases

Abstract

A compound which acts as an antagonist at 5-HT 4 receptors is of potential use in the treatment of conditions associated with bladder hypersensitivity, such as urinary incontinence, which is often associated with irritable bowel syndrome (IBS) and a compound which acts as an agonist at 5-HT 4 receptors is of potential use in the treatment of conditions associated with a poorly functioning bladder, such as urinary bladder hypoactivity following prostectomy.

What is claimed is:  
     
       1. A method for the treatment of a condition associated with bladder hypersensitivity, said condition being urinary incontinence in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of a 5-HT 4  receptor antagonist. 
     
     
       2. A method according to  claim 1  which is for the treatment of urinary incontinence associated with irritable bowel syndrome. 
     
     
       3. A method according to  claim 1 , wherein the 5-HT 4  receptor antagonist is: 
       (i)                    
       (ii) 2-methoxy-4-amino-5-chloro-benzoic acid 2-(diethylamino) ethyl ester, or  
       (iii)                    
       (iv) 3-(piperidin-1-yl)propyl 4-amino-5-chloro-2-methoxybenzoate hydrochloride.  
     
     
       4. A method as claimed in  claim 1 , wherein the 5-HT 4  receptor antagonist is more potent at 5-HT 4  receptors than at 5-HT 3  receptors. 
     
     
       5. A method as claimed in  claim 1 , wherein the mammals are humans. 
     
     
       6. A method as claimed in  claim 4 , wherein the mammals are humans.